T-CYPHER BIO
T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of such therapies. T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.
T-CYPHER BIO
Social Links:
Industry:
Biotechnology
Founded:
2020-08-27
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.tcypherbio.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Amazon Bamboo HR
Similar Organizations
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
ExoLytics
ExoLytics is an early-stage biotechnology company.
Fortis Biosciences
Fortis Biosciences is an early-stage biotech startup company.
Homebiotic
Homebiotic is an environmental probiotic technology developer company.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Onward Therapeutics
Onward Therapeutics is a development stage oncology company.
ProNeurogen
ProNeurogen is an early-stage biotech company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Oxford Science Enterprises
Oxford Science Enterprises investment in Seed Round - T-Cypher Bio
Official Site Inspections
http://www.tcypherbio.com
- Host name: sites.framer.app
- IP address: 31.43.161.6
- Location: Makiyivka Ukraine
- Latitude: 48.0478
- Longitude: 37.9258
- Timezone: Europe/Kiev
- Postal: 20754
More informations about "T-Cypher Bio"
T-Cypher Bio
Jul 29, 2020 Professor Sir Andrew McMichael. Prof Sir Andrew McMichael has worked on T cell immune responses in humans since the 1970s. He was first to demonstrate virus-specific …See details»
T-Cypher Bio - Crunchbase Company Profile & Funding
T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of …See details»
T-Cypher Bio - LinkedIn
At T-Cypher Bio we generate novel TCR-based therapeutics that have the potential to transform the treatment of immune-mediated disease. Our proprietary platforms provide unique insight into T cell ...See details»
T-Cypher Bio - Company Profile & Staff Directory - ContactOut
T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of solid …See details»
T-Cypher Bio 2025 Company Profile: Valuation, …
Dec 21, 2020 T-Cypher Bio General Information Description. Developer of T-cell receptor-based therapeutics intended to provide a novel approach to cancer …See details»
T-Cypher Bio - VentureRadar
Website: https://tcypherbio.com. Develops TCR-based therapeutics for solid tumors, autoimmune, inflammatory, and infectious diseases using a proprietary automated microfluidic discovery …See details»
T-Cypher Bio - Products, Competitors, Financials, Employees ...
About T-Cypher Bio. T-Cypher Bio is a biotechnology company focused on the development of TCR-based therapeutics within the healthcare sector. The company develops therapeutics for …See details»
T-CYPHER BIO LIMITED - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for T-CYPHER BIO LIMITED of OXFORD. Get the latest business insights from Dun & Bradstreet.See details»
T-Cypher Bio Announces Formation of Scientific Advisory Board
Email: [email protected] Amber Fennell / Alexandra Harrison / Aaron Kelly Phone: +44 (0)20 3709 5701 Email: [email protected] About T-Cypher Bio T-Cypher Bio, a …See details»
T-Cypher Bio - Oxford Science Enterprises
Tcypherbio.com. T-Cypher Bio is an early stage T-cell target and T-cell receptor (TCR) discovery and validation company developing the next generation of TCR-based therapeutics by deploying novel, high-throughput, platforms. What Life …See details»
T-Cypher Bio – Funding, Valuation, Investors, News
Jul 29, 2021 T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of …See details»
T-Cypher Bio announces the appointment of Thomas Lars …
Email: [email protected] Amber Fennell / Alexandra Harrison / Aaron Kelly Phone: +44 (0)20 3709 5701 Email: [email protected] About T-Cypher Bio T-Cypher Bio, a …See details»
T-Cypher Bio - Leadership Team - The Org
The Leadership Team at T-Cypher Bio drives the strategic vision and operational execution of the company's mission to revolutionize TCR-based therapeutics.See details»
T-Cypher Bio Ltd.. (7/15/21). "Press Release: T-Cypher Bio …
BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry Association (BIA) …See details»
T-Cypher Bio – Funding, Valuation, Investors, News | Parsers VC
Jul 29, 2021 T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of …See details»
T-Cypher Bio Reviews, Funding, Founder, Valuation & Jobs
Find out if T-Cypher Bio is hiring now! Explore jobs, salary, equity, funding, founder, and valuationn information. Read about work-life balance, perks, benefits, and the company culture!See details»
T-Cypher Bio separates from Orbit Discovery to build a
Feb 25, 2021 Email: [email protected]: Amber Fennell / Alexandra Harrison / Aaron Kelly Phone: +44 (0)20 3709 5701 Email: [email protected] ...See details»
T-Cypher Bio announces the appointment of Thomas Lars …
T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer Company to be led by award winning, cell therapy expert as it aims to unlock an expansive …See details»
T-Cypher Bio - EU-Startups
T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as …See details»
T-Cypher Bio separates from Orbit Discovery to build a pipeline of …
Feb 25, 2021 PRESS RELEASE T-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics for solid tumours and other indications Company has potential to unlock …See details»